Immunotherapy in gliomas Journal Article


Authors: Weant, M. P.; Mejías-De Jesús, C.; Yerram, P.
Article Title: Immunotherapy in gliomas
Abstract: OBJECTIVES: To describe the immunotherapy approaches currently under investigation for the treatment of gliomas. To discuss the management of immune-related adverse effects. DATA SOURCES: Published literature, clinical trials, and oncology association guidance documents. CONCLUSION: There are numerous modalities of immune treatment currently being evaluated in patients with glioma, including peptide vaccines, dendritic cell vaccines, oncolytic viruses, CAR-T cells, and checkpoint inhibitor therapy. Immunotherapy utilizes new mechanisms of treatment that may lead us to the eradication of gliomas. IMPLICATIONS FOR NURSING PRACTICE: Immunotherapy is a rapidly growing field in the treatment of gliomas. Oncology nurses are often involved in the safe administration of these therapies, as well as the identification and management of immune-related toxicities.
Keywords: temozolomide; glioma; immunotherapy; glioblastoma; safety; antibody; trial; phase-3; rindopepimut; immune-related adverse events
Journal Title: Seminars in Oncology Nursing
Volume: 34
Issue: 5
ISSN: 0749-2081
Publisher: Elsevier Inc.  
Date Published: 2018-12-01
Start Page: 501
End Page: 512
Language: English
ACCESSION: WOS:000451586100010
DOI: 10.1016/j.soncn.2018.10.011
PROVIDER: wos
PUBMED: 30396808
Notes: Review -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Prakirthi Yerram
    9 Yerram